Abstract 1600P
Background
Sarcopenia is a disorder that causes muscle mass and strength loss, which can result in diminished mobility and functional limits. Depression and a bad assessment of one's own health are common results among cancer patients. As a result, this study aimed to look at the association between sarcopenia, depression, and health perception.
Methods
Cancer patients were the subject of a retrospective study from January to April 2023. The study included 150 patients who had different forms of a verified cancer diagnosis. These individuals were admitted to Mayo Hospital's Palliative Care Cancer Department. The presence of depressive symptoms was assessed using the Patient Health Questionnaire (PHQ-9). SARC-F was used to measure all the five dimensions of sarcopenia. To examine self-perceived health, a self-report questionnaire was used. The relationships between sarcopenia, depression, and health perception were investigated using correlation analysis.
Results
We observed a significant and positive association between depression and the dimensions of sarcopenia. Specifically, we found a positive correlation between depression and SARC1=Strength (r = 0.378, p<0.01), SARC2=Assistance in walking (r = 0.390, p<0.01), SARC3=Rise from a chair (r = 0.488, p<0.01), and SARC4=Climb stairs (r = 0.392, p<0.01). However, we found a positive but insignificant relationship between depression and SARC5=Falls (r = 0.150, p>0.05). In addition, we discovered that patients' perception of poor health was correlated with depression (r = -0.391, p<0.01), SARC2=Assistance in walking (r = -0.235, p<0.01), SARC3=Rise from a chair (r = -0.259, p<0.01), and SARC4=Climb stairs (r = -0.277, p<0.01). However, we did not find a significant relationship between health perception and two dimensions of sarcopenia (i.e., SARC1=Strength and SARC5=Falls).
Conclusions
Sarcopenia adversely affects the physical and mental health of cancer patients. They feel depressed and perceive their health as bad which imparts a negative impact on the outcome of these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - End-of-life hospital cancer care in the COVID-19 era: A retrospective population-based study in the Netherlands
Presenter: Ellis Slotman
Session: Poster session 05
1595P - Incidence and characterization of end-of-life (EoL) systemic anticancer therapy (SACT) in melanoma patients (pts): A monocentric experience
Presenter: Silvia Buriolla
Session: Poster session 05
1596P - Exploring the economic impact of palliative care in oncology at the end of life
Presenter: Sarah Gomes
Session: Poster session 05
1597P - Improving in-hospital end-of-life care (EOLC) for oncology patients in a tertiary cancer centre
Presenter: Conor Moloney
Session: Poster session 05
1598P - Differences in referral patterns to the palliative care team among specialized physicians in patients with terminal cancer
Presenter: Hyun Jeong Shim
Session: Poster session 05
1599P - Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study
Presenter: Alessandro Leonetti
Session: Poster session 05
1601P - Relationship between CT and ultrasonography-based sarcopenia and hematologic toxicity in patients with cancer receiving chemotherapy
Presenter: Gurkan Guner
Session: Poster session 05
1602P - Simulation training for compassionate extubation in the pediatric intensive care unit
Presenter: Nicole Fernandez
Session: Poster session 05
1603P - The ability of the LACE index to predict 30-day readmissions in oncology patients
Presenter: Burcu Ulas Kahya
Session: Poster session 05
1604P - A comparative study of symptom prevalence between adults and elderly patients with advanced cancer diagnosis under palliative care: A single institution experience
Presenter: Hodan Abdullah
Session: Poster session 05